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Abstract
Background: Autophagy is a major pathway of protein and organelle degradation in the lysosome. Autophagy
exists at basal constitutive level and can be induced as a defense mechanism under stress conditions. Molecular
relationships between autophagy and inflammation at the periphery were recently evidenced, highlighting a role of
autophagy in the regulation of inflammation. Impairment of autophagy (with accumulation of autophagic vacuoles)
and substantial inflammation are found in neurodegenerative diseases such as Alzheimer’s Disease (AD). However,
the links between autophagy and inflammation in AD remain to be determined.
Methods: Here, we examined the inflammatory reaction and autophagy in murine tri-cultures of neurons, astrocytes,
and microglia. Tri-cultures were exposed to various inflammatory stresses (lipopolysaccharide (LPS), amyloid peptide
(Aβ42) with or without cytokines) for 48 hours. Furthermore, the relationships between inflammation and autophagy
were also analyzed in astrocyte- and microglia-enriched cultures. Data for multiple variable comparisons were analyzed
by a one-way ANOVA followed by a Newman-keuls’ test.
Results: Aβ42 induced a low inflammation without accumulation of acidic vesicles contrary to moderate or severe
inflammation induced by LPS or the cytokine cocktail (IL-1β, TNF-α, and IL-6) or IL-1β alone which led to co-localization
of p62 and LC3, two markers of autophagy, with acidic vesicles stained with Lyso-ID Red dye. Moreover, the study
reveals a major role of IL-1β in the induction of autophagy in tri-cultures in the presence or absence of Aβ42.
However, the vulnerability of the autophagic process in purified microglia to IL-1β was prevented by Aβ42.
Conclusion: These findings show a close relationship between inflammation and autophagy, in particular a
major role of IL-1β in the induction of the microglial autophagy which could be the case in AD. New therapeutic
strategies could target inflammasome and autophagy in microglia to maintain its role in the amyloid
immunosurveillance.
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Background
Macroautophagy (hereafter ‘autophagy’), a basal house-
keeping process, delivers a wide spectrum of cytosolic
substrates including long-lived proteins, protein aggre-
gates, and organelles to lysosomes for subsequent deg-
radation. In addition to its role in cellular homeostasis,
autophagy plays an essential role in the development of
innate and adaptive immune responses and in physio-
logical responses to exercise and aging. Autophagy can
also be induced by various environmental and cellular
stresses, such as nutrient starvation, trophic factor with-
drawal, and immune stimuli [1]. Autophagy is mainly
regulated by two key kinases and nutrient sensors: the
mammalian target of rapamycin (mTOR), a Ser/Thr kin-
ase which inhibits autophagy, and AMP-activated protein
kinase (AMPK), a positive regulator of autophagy [2].
Dysfunctions of autophagy are widely implicated in
pathological conditions, including cancer, metabolic and
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neurodegenerative disorders, and cardiovascular and
pulmonary diseases [3]. However, molecular mecha-
nisms underlying these connections are not completely
elucidated. Downregulation of both IFN responses to
viral infection and proinflammatory cytokine responses to
invading pathogens and the inhibition of inflammasome-
dependent maturation and secretion of proinflammatory
cytokines (for example, IL-1β) have been demonstrated
[4-6]. The first link between autophagy and inflammation
was established by the discovery that the inflammatory
Crohn’s disease is linked to the mutations of Atg16L1, a
key component of the core machinery of autophagy. Fol-
lowing stimulation by lipopolysaccharide (LPS), autophagy-
related protein 16-1 (Atg16L1)-deficient macrophages
produce high amounts of the proinflammatory cyto-
kines IL-1β and IL-18, suggesting that autophagy might
have an inhibitory effect on the maturation and secretion
of proinflammatory cytokines [7].
Currently, no studies have examined the potential
links between autophagy and inflammation activation in
the context of central nervous system (CNS) disease. At
early stages of Alzheimer’s disease (AD), autophagy is in-
duced in vulnerable neurons of AD patients and in a
transgenic mouse model [8,9]. A reduced expression of
the autophagy-related protein Beclin-1, which is required
for the early step of autophagosome formation [10], and
co-localization of sequestosome 1/p62 (an adaptor protein
with several functional domains to target polyubiquiti-
nated protein cargo to autophagosomes), ubiquitin, and
hyperphosphorylated tau in aggregates have been reported
in the cortex and hippocampus of AD patients [11,12].
Furthermore, in familial AD, autophagosomes proliferated
and the level of LC3-II (a marker of autophagosome) in-
creased [13]. In addition, components required for the
generation of Aβ (amyloid precursor protein (APP), prese-
nilin 1 (PS1), nicastrin, and β-secretase) are found in au-
tophagic vacuoles (AVs) [14].
Besides, several lines of evidence suggest that inflam-
mation plays a key role in the pathogenesis of AD [15].
Recently, amyloid-β-induced activation of the NLRP3
inflammasome was demonstrated to enhance AD pro-
gression by mediating harmful chronic inflammation tis-
sue response [16].
In the present study, we set out to investigate the in-
teractions between autophagy and inflammation in AD.
Firstly, in primary tri-cultures of neurons, astrocytes,
and microglia, we showed that an inflammatory stress,
particularly driven by IL-1β, induced autophagy with
acidic vesicle accumulation contrary to amyloid peptide
(Aβ42). Immunolabeling in tri-cultures showed that only
microglia displayed an accumulation of acidic vesicles as
demonstrated in Lyso-ID Red-stained cells under inflam-
matory stress. Secondly, on purified cultures of astro-
cytes or microglia, we confirmed that only in microglia
the autophagic process was sensitive to IL-1β, while
Aβ42 prevented the accumulation of acidic vesicles.
These close relationships between inflammasome and
autophagy in the AD model could open new therapeutic




Sodium fluoride (NaF), phenylmethylsulfonyl fluoride
(PMSF), protease and phosphatase inhibitor cocktails,
dithiothreitol (DTT), 0.01% poly-L-lysine (PLL) solution,
Percoll, sterile filtered dimethyl sulfoxide (DMSO) Hybri-
Max, Triton X-100, paraformaldehyde (PFA), and all
reagent-grade chemicals for buffers were purchased
from Sigma-Aldrich (Saint-Quentin Fallavier, France).
Dulbecco’s modified Eagle’s medium (DMEM) (1 g/L
and 4.5 g/L glucose), F-12, minimum essential medium
Eagle (MEM) and neurobasal media, B-27 supplement,
200 mM L-glutamine, 5,000 units of penicillin (base)
and 5,000 μg of streptomycin (base)/mL (penicillin-
streptomycin (PS)) mixture, 0.05% trypsin-EDTA (1X)
phenol red, FBS certified, horse serum, NuPAGE Novex
3-8% Tris-Acetate and Novex 4-20% Tris-Glycine gels,
NuPAGE LDS Sample Buffer (4X), NuPAGE Sample Re-
ducing Agent (10X), Novex Tris-Glycine and NuPAGE
Tris-Acetate SDS Running Buffer, NuPAGE Antioxidant,
iBlot transfer stack regular (nitrocellulose), and the
ProLong Gold antifade reagent with 4′,6-diamidino-
2-phenylindole (DAPI) were purchased from Gibco-
Invitrogen (Fisher Scientific distributor, Illkirch, France).
The β-amyloid peptide (Aβ42) and imidazole-oxindole
compound C16 were purchased from Merck Chemicals
Calbiochem (Merck Millipore, Billerica, MA, USA). Pri-
mary antibodies and secondary anti-rabbit IgG antibody
conjugated with horseradish peroxidase (HRP) and re-
combinant cytokines (TNF-α, IL-1β, and IL-6) were
purchased from Cell Signalling (Ozyme, Saint-Quentin-
en-Yvelines, France) except LC3 and p62/SQMT1 from
MBL (CliniSciences distributor, Nanterre, France), anti-β
actin from Sigma-Aldrich, and HRP conjugated anti-
mouse IgG from Fisher Scientific. For immunofluores-
cence, mouse anti-glial fibrillary acidic protein (GFAP)
antibodies were purchased from Cell Signalling, chicken
anti-microtubule-associated protein 2 (MAP2) from
Abcam (Paris, France), rat anti-macrosialin (murine
homologue of the human CD68) from AbD Serotec
(Düsseldorf, Germany), and secondary antibodies: swine
anti-rabbit fluorescein isothiocyanate (FITC) and tetra-
methylrhodamine isothiocyanate (TRITC) from DakoCy-
tomation (Trappes, France), goat anti-mouse Alexa 647
from Invitrogen (Fisher Bioblock Scientific distributor,
Illkirch, France), goat anti-chicken-FITC from Abcam
(Paris, France), and IgG- and protease-free bovine
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serum albumin (BSA) from Jackson ImmunoResearch
Europe, Ltd (Beckman-Coulter distributor, Villepinte,
France).
Murine primary cultures
The experiments using animals have made a request to
the local ethics committee according to “La direction
départementale de la protection de la population (DDPP)”
protocol was registered under the number 07.12. Any ex-
perimental research on animals followed internationally
recognized guidelines.
Neurons/astrocytes/microglia
The tri-culture was obtained as previously described
[17]. First, primary glial cultures were prepared from
B6C3F1 mouse embryos of 18 days. Briefly, brains were
quickly removed, and cerebral cortico-hippocampal re-
gions were dissected. Cells were then mechanically dis-
sociated and suspended into DMEM (1 g/L glucose)/F12
(1:1) with 10% FBS/1% of antibiotic PS, seeded at a dens-
ity of 4 × 105 cells/mL in Nunc EasYFlask (75 cm2)
coated with 0.001% PLL, and then incubated at 37°C in
a humidified 5% CO2 atmosphere. After 14-day-old cul-
tures, microglia was purified.
Second, primary cultures with neurons and astrocytes
were prepared from the cortex and hippocampus of
B6C3F1 mouse embryos of 18 days as indicated above.
Cells were suspended in MEM/neurobasal (1:1) supplied
with 18 mM glucose, 2% B-27 supplement, 1% glutam-
ine, 2.5% FBS, 2.5% horse serum, and 1% PS, and seeded
in 6-well plates (8.25 × 105 cells per well) coated with
0.001% PLL. Cultures were then maintained at 37°C in a
humidified 5% CO2 atmosphere. At day 5, neurons and
astrocytes were cultured with microglia purified from
the primary glial culture described above.
Third, microglia was purified from glial cultures on
day 14 on the Percoll gradient as previously described
[17]. Purified microglia was added at the proportion of
15% of the initial density of 5-day-old primary neuron
and astrocyte cultures. The obtained tri-cultures were
then used 3 days later in the experimental conditions.
Astrocyte-enriched cultures
Primary astrocyte cultures were prepared from the cor-
tex and hippocampus of B6C3F1 mice aged 2 days. Cells
were suspended in DMEM (4.5 g/L glucose), 1% glutam-
ine, 10% FBS, 1% PS, and seeded in 6-well plates (8.25 ×
105 cells per well) coated with 0.001% PLL. Cultures were
then maintained at 37°C in a humidified 5% CO2 atmos-
phere. These cells were used 8 days later in experiments.
Microglial cell-enriched cultures
Primary microglia cultures were prepared as described
above and purified microglia were seeded in 6-well
plates (3.75 × 105 cells per well) coated with 0.001% PLL.
Cultures were then maintained at 37°C in a humidified
5% CO2 atmosphere and used 3 days later in experi-
ments. The enrichment of microglial cells in these cul-
tures was approximately 79 ± 10% of microglia (n = 5 in
duplicate, five fields per coverslip).
Culture treatments
Tri-cultures, purified astrocytes, and microglia cultures
were treated with either C16 (a specific inhibitor of
double-stranded RNA-dependent protein kinase (PKR))
at 210 nM or 0.2% DMSO (vehicle of C16), in serum-
free MEM:neurobasal (1:1)/1% glutamine/1% PS medium
for tri-cultures, serum-free DMEM, 1% glutamine, 1% PS
for astrocytes, and serum-free DMEM/F12 (1:1)/1% PS for
microglia, 1 hour before inflammatory stress. The concen-
tration of C16 was chosen as previously described in these
primary tri-cultures [17]. All cultures were exposed to dif-
ferent inflammatory stresses for 48 hours: Aβ42 used at
20 μM and was previously incubated for 72 hours at 37°C
for aggregation as recommended by the Merck Chemical
supplier (this Aβ42 solution contains monomers at 4 kDa,
oligomers at 8 and 12 kDa, and fibrils as described by
Couturier et al. [17]); LPS used at 100 ng/mL; and mouse
recombinant TNF-α, IL-1β, or IL-6 cytokines used at
200 pg/mL alone or in combination (‘cocktail’ condition).
After 24 hours, cultures were treated with an autophagic
inhibitor, bafilomycin A1 (Baf), at 50 nM for 24 hours.
Cell lysis
After 48 hours of treatment, media were stored at -80°C
until used for xMAP (Luminex, Austin, TX, USA) assays.
Cells were then washed with PBS (1.54 mM KH2PO4,
154 mM NaCl, and 2.71 mM Na2HPO4-7H2O) and lysed
in ice-cold lysis buffer (50 mM Tris-HCl, 50 mM NaCl,
pH 6.8, 1% (v/v) Triton X-100, 1 mM PMSF, 50 mM
NaF, 1% (v/v) protease inhibitor, and 1% (v/v) phosphat-
ase inhibitor cocktail). Lysates were sonicated for 10 sec-
onds and centrifuged at 15,000 × g for 15 minutes at 4°C.
The supernatants were collected and analyzed for pro-
tein determination using a Qubit protein assay kit
(Fisher Scientific). Samples were frozen at -80°C until
further analysis.
Immunoblotting
Samples (40 μg protein of cell lysates) were prepared for
electrophoresis by adding NuPAGE LDS Sample Buffer
(4X) and NuPAGE Sample Reducing Agent (10X). After
heating, samples were loaded into NuPAGE Novex 4-
20% Tris-Glycine Mini Gels, run at 150 V for 60 minutes
in Novex Tri- Glycine SDS Running Buffer containing
NuPAGE Antioxidant and in NuPAGE 3-8% Tris-Acetate
Gels, run at 125 V for 120 minutes in Novex Tris-Acetate
SDS Running Buffer containing NuPAGE Antioxidant.
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Gels were transferred to nitrocellulose membranes using
the iBlot Dry Blotting System set to program 20 V for
7 minutes. Membranes were washed for 10 minutes in
Tris-buffered saline and Tween (TBST) (20 mM Tris-
HCl, 150 mM NaCl, pH 7.5, and 0.05% Tween 20) and
blocked for 2 hours in TBST containing 5% BSA. Blots
were incubated with primary antibody in blocking buffer
overnight at 4°C. Antibodies used were rabbit anti-Beclin-1
(1:500), rabbit anti-p62/SQMST1 (1:500), rabbit anti-LC3
(1:500), rabbit anti-mTOR (1:500), rabbit anti-PS2448
mTOR (1:500), rabbit anti-p70S6K (1:500), and rabbit
anti-PT389-p70S6K (1:500). Membranes were washed
twice with TBST and then incubated with the peroxid-
ase conjugated secondary anti-rabbit antibody (1:1,000)
for 1 hour at room temperature. Membranes were washed
again and exposed to the chemiluminescence Luminata
Forte Western HRP Substrate (Millipore, Saint-Quentin-
en-Yvelines, France) followed by signal capture with the
Gbox system (GeneSnap software, Syngene, Ozyme dis-
tributor). After two washes in TBST, membranes were
probed with mouse antibody against β-actin (1:100,000)
overnight at 4°C. They were then washed with TBST, incu-
bated with peroxidase conjugated secondary anti-mouse
antibody (1:1,000) for 1 hour, exposed to the chemilumin-
escence Luminata Classico Western HRP Substrate, and
signals were captured. Automatic image analysis software
was supplied with GeneTools (Syngene). Ratios of pro-
tein/β-actin and phosphorylated protein/total protein
(represented activation of kinase) were calculated and
shown in the corresponding figures.
Luminex xMAP assay
Mouse cytokine Luminex 3-plex kits (for TNF-α, IL-1β,
and IL6) were purchased from Millipore. The assay was
performed in 96-well plates and all reagents and plates
were prepared according to the manufacturers’ instruc-
tions. Each standard (25 μL) from a range of concentra-
tions (10,000 to 3.2 pg/mL) (assay buffer was used as a
blank), quality controls, and samples were added to the
relevant wells. The culture media and cell lysis buffer
were added as background controls. The mixed bead so-
lution was sonicated and vortexed prior to adding 25 μL
into each well. The plates were sealed and incubated
with agitation on a plate shaker at 750 rpm (Titrimax,
Fisher Scientific) overnight at 4°C in a darkroom. Plates
were washed twice with 200 μL assay wash buffer, and
25 μL biotinylated detection antibodies were added per
well. The samples were incubated for 1 hour at room
temperature on the plate shaker at 750 rpm in a darkroom.
Without washing, 25 μL/well of streptavidin-phycoerythrin
solution was added, and plates were incubated for another
30 minutes at room temperature on a plate shaker at
750 rpm in a darkroom. After staining was complete, the
microbeads were washed twice with 200 μL/well wash
buffer. The microbeads were resuspended in 150 μL/well
of Luminex Sheath Fluid on a plate shaker at 500 rpm for
5 minutes at room temperature before analyzing. The assay
was acquired on a Luminex 200 instrument using xPO-
NENT software (Luminex). An acquisition gate of between
8,000 and 15,000 was set to discriminate against any doub-
let events and ensure that only single microbeads were
measured. A total of 50 beads/well were collected and me-
dian fluorescence intensities (MFIs) were measured. The
sensitivity limit was 5.4, 1.1, and 2.3 pg/mL for IL-1β, IL-6,
and TNFα, respectively. The MFIs were converted to con-
centrations using the best parameter logistic fit curve
generated for each analyte from the six standards using
Milliplex Analyst software (Millipore). Results were
expressed as pg/mL for culture media and pg/mg pro-
tein for cell lysates.
Confocal immunocytofluorescence
After treatment, cells were washed with PBS and fixed
with 4% PFA for 15 minutes at room temperature. After
three washes with PBS, the permeabilizing and blocking
PBS buffer (137 mM NaCl, 2.7 mM KCl, 1.7 mM KH2PO4,
10.14 mM Na2HPO4, pH 7.4, containing 0.3% triton X-100
and 5% BSA) was added for 1 hour at room temperature.
In tri-cultures, staining of neurons, astrocytes, micro-
glia, and autophagosomes was performed by incubating
coverslips overnight at 4°C with a mix containing chicken
anti-MAP2 (1:50), mouse anti-GFAP (1:100) with a rabbit
anti-p62 (1:50) or rabbit anti-LC3 (1:50), or a mix with rat
anti-CD68-R-phycoerythrin (RPE) (1:25), mouse anti-
GFAP (1:100) with a rabbit anti-p62 or rabbit anti-LC3
(1:25) in PBS containing 0.3% triton X-100 and 1%
BSA. In purified primary microglia, a mix solution
containing rat anti-CD68-RPE (1:25), mouse anti-GFAP
(1:100) with a rabbit anti-p62 (1:50) or rabbit anti-LC3
(1:50) was used. Cells were then rinsed twice with PBS be-
fore 1 hour of incubation at room temperature either with
a mix containing swine anti-rabbit TRITC (1:20) for p62
or LC3, goat anti-chicken FITC (1:50) for MAP2, goat
anti-mouse Alexa Fluor 647 (1:25) for GFAP to study p62
or LC3 expression in neurons and astrocytes of tri-
cultures, or a mix containing swine anti-rabbit FITC
(1:30) for p62 or LC3, goat anti-mouse Alexa Fluor 647
(1:25) for GFAP to study p62 or LC3 expression in astro-
cytes and microglia of tri-cultures and in purified micro-
glia. Finally, cells were washed twice in PBS and twice in
distilled water before mounting with the ProLong Gold
antifade reagent with DAPI.
Lysosome activity assessment
In order to detect lysosome and lysosome-like organelle
perturbations in our experimental conditions, we used
Lyso-ID Red Cytotoxicity Kit (GFP-Certified) (Enzo Life
Sciences, Exeter, UK) for 96-well microplates. According
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to this assay, an increase in the red lysosome signal indi-
cates the accumulation of Lyso-ID Red dye within the
cells reflecting an increase in lysosome or lysosome-like
vesicle size and/or number. However, quantification of
fluorescence was not performed because in our experi-
mental conditions all cells were not fluorescent and thus
the fluorescent intensity was under the limit of detection
contrary to the positive control with verapamil, a cat-
ionic amphiphilic drug, known to cause phospholipido-
sis, the accumulation of phospholipids in acidic
organelles in the cells, and used by the manufacturer to
validate the assay. Thus, after treatment, tri-cultures or
purified microglia were washed once with 100 μL of 1X
assay buffer and incubated with 100 μL of the 1X Lyso-
ID Red reagent in a darkroom for 30 minutes at room
temperature. Then, cells were washed twice with 200 μL
of 1X assay buffer per wash and fixed with 4% PFA for
immunocytofluorescence as described above to study
co-staining with p62 and LC3.
Multiple labeled samples were examined with a spec-
tral confocal FV1000 station installed on an inverted
microscope IX-81 (Olympus, Tokyo, Japan) with Olym-
pus X40 oil, 1.2 NA, and an objective lens with optical
section separation (z-interval) of 0.6 μm. Fluorescence
signal collection, image construction, and scaling were
performed using the control software (Fluoview FV-
AS10, Olympus). Multiple fluorescence signals were ac-
quired sequentially to avoid cross-talk between image
channels. Fluorophores were excited with a 405 nm line
of a diode (for DAPI), 488 nm line of an argon laser (for
Alexa Fluor 488 or FITC), 543 nm line of a helium–
neon laser (for TRITC and RPE), and 633 nm line of a
helium–neon laser (for Alexa Fluor 647). Emitted fluor-
escence was detected through spectral detection chan-
nels between 425 to 475 nm and 500 to 530 nm, for
blue and green fluorescence, respectively, and through
560 nm and 650 nm long pass filters for red and far red
fluorescence, respectively. The images then were merged
as an RGB image. Signals were analyzed by ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA).
For each channel in the merged image, the intensity of sig-
nal in neurons, astrocytes, and microglia were analyzed by
enclosing cells using the tools available in the software.
Co-labeling analyses between Lyso-ID and p62 or LC3
were performed by using Imaris software (version 7.4.2,
Bitplane, Zurich, Switzerland) in a region of interest
(ROI). Two-dimensional fluorograms displayed the in-
tensity and distribution of different colored pixels within
the merged image as a scattergram generated for each
analysis.
Statistical analysis
Results are expressed as means ± SEM. Data for multiple
variable comparisons were analyzed by a one-way ANOVA
followed by a Newman-Keuls’ test as a post hoc test using
the statistical program GraphPad InStat (GraphPad Soft-
ware, San Diego, CA, USA). The level of significance
was P <0.05.
Results
At first, we studied the impact of inflammatory stress on
autophagy in tri-cultures of neurons, astrocytes, and
microglia, a model previously published [17]. This model
brings together the major cellular players of the CNS in-
cluding neurons (36%), astrocytes (57%), and microglia
(6%), and seems necessary to answer our question, tak-
ing into account the cellular and molecular responses of
these three cell types in the same environment that
models the CNS.
Levels of cytokines in primary tri-cultures exposed to LPS
or Aβ42
LPS is the major component of the outer membrane
of gram-negative bacteria and is well reported to in-
duce inflammatory response and cytokine production
through the NF-κB signaling pathway [18,19]. C16 is
a specific imidazolo-oxindole inhibitor of PKR and
can prevent the NF-κB signaling pathway and cyto-
kine production [17,20-22].
As expected, 48 hours of treatment of tri-cultures of
neurons/astrocytes/microglia with 100 ng/mL LPS in-
duced a substantial increase in the levels of intracellular
and released cytokine (Figure 1). Intracellular and re-
leased IL-1β levels were 7.5 and 177 times higher, re-
spectively, compared to control values (Figure 1A,D).
TNF-α levels were increased by a factor of 113 and
1,200, respectively (Figure 1B,E) and IL-6 levels were
increased by a factor of 619 and 330, respectively
(Figure 1C,F).
Pre-treatment with 210 nM C16 significantly de-
creased levels of LPS-induced cytokines except for re-
leased IL-6. Intracellular levels of all cytokines were
decreased by 70% to 80% (Figure 1D,E,F) and reductions
in TNF-α and IL-1β in the extracellular medium were
50% and 90%, respectively (Figure 1A,B). Interestingly,
the prevention of LPS-induced cytokine levels was
complete for released IL-1β (Figure 1A) and TNF-α
and IL-6 in cell lysates (Figure 1E,F, respectively), but
partial for IL-1β in cell lysates and released TNF-α
(Figure 1B,D). C16 failed to prevent LPS-induced in-
crease of released IL-6 (Figure 1C).
Exposure of tri-cultures to Aβ42 20 μM for 48 hours
induced a very low inflammation stress of less than
10 μg/mg protein and 20 pg/mL in cell lysates and extra-
cellular medium, respectively. These values are compar-
able to those observed in controls (in the presence or
absence of C16) (Figure 1).
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Monitoring of the autophagic flux in primary tri-cultures
exposed to LPS or Aβ42
To determine whether autophagy changes occur during
an inflammatory stress, Beclin-1, p62, LC3-I, and LC3-II
were investigated. Beclin-1 is a key component of the
class III phosphatidylinositide 3-kinase (PI3K) complex
which is involved in the initiation of autophagosome for-
mation [23]; p62 is an autophagic receptor which recog-
nizes ubiquitinylated proteins and interacts with LC3-II
at the forming autophagosome [24]; LC3 is present in a
free cytoplasmic form as LC3-I which when it is associated
with phosphatidylethanolamine (through an ubiquitin-like
conjugation reaction) of the membrane of autophagosome
produces LC3-II, a useful marker of autophagic mem-
branes. LC3-II migrates to an apparently lower Mr position
(LC3-II) by electrophoresis [24]. Both p62 and LC3-II are
degraded with ubiquitinylated protein after autophagosome
fusion with lysosome. To understand whether autophagy
was impaired in our experimental conditions, an autopha-
gic flux inhibitor, Baf, has been used in particular to detect
LC3-II which is difficult to quantify during autophagic flux.
This toxin blocks the lysosome acidification required for
the fusion with autophagic vacuole by specific inhibition of
the vacuolar-type H+-ATPase lysosomal pump [25]. It
should be noted that Baf did not modify LPS-induced in-
creases in cytokines. Furthermore, in the presence of Baf,
C16 partially reduced levels of all intracellular cytokines
(46% to 56% of inhibition) and of extracellular TNF-α and
IL-1β (37% and 73%, respectively) except for released IL-6
[see Additional file 1].
As expected, LPS-treated tri-cultures displayed a very
reactive microglia, marked by a larger cell body and nu-
merous radiating cytoplasmic projections (Figure 2C,E).
LPS clearly affected neuron viability which is manifested
by the presence of highly condensed nuclei and the ab-
sence/retraction of neurites. Astrocytes were protoplasmic
but some were stellar [see Additional file 2]. Conversely,
in control or Aβ42 conditions, neurons had long processes
in communication with others, microglia remained ‘rest-
ing’, and astrocytes drew a very protoplasmic layer of cells
(Figure 2C,E) [see Additional file 2].
The expression of p62 was significantly increased by
LPS treatment (194% increase) but C16 failed to reverse
this increase (Figure 2A). Blockade of the autophagic
flux by Baf increased p62 expression (450% increase
compared to control) but LPS further enhanced the level
of p62 in the presence of Baf inhibitor and again C16
failed to reverse the p62 increase. Interestingly, Aβ42
had no effect alone but significantly decreased (by 30%)
p62 expression in the presence of Baf.
The co-labeling of p62, MAP2 for neurons, GFAP for
astrocytes, and CD68 for microglia in the tri-culture
Figure 1 Cytokine levels induced by LPS or Aβ42 in primary tri-cultures. Cytokine (IL1-β, TNF-α, and IL-6) levels in culture medium (A, B, C,
respectively) and in cell lysates (D, E, F, respectively) of tri-cultures pre-treated or not with 210 nM C16 and treated with 100 ng/mL LPS or with
20 μM Aβ42 in serum-free medium were analyzed by the 3-plex Luminex xMAP assay containing a mixture of specific beads for each cytokine as
described in the Methods section. Cytokine levels in culture medium and cell lysates are expressed in pg/mL and pg/mg protein, respectively. Results
are mean ± SEM for six experiments in duplicate. ***P <0.001 compared to control; ##P <0.01, ###P <0.001 compared to LPS; ††P <0.01, †††P <0.001 com-
pared to C16 by one-way ANOVA with a Newman-Keuls multiple comparison test. LPS, lipopolysaccharide; NS, not significant.
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showed that LPS causes accumulation of p62 specifically
in microglia (Figure 2C for microglia and see Additional
file 2 for neurons and astrocytes). In situ quantification
of p62 fluorescence intensity showed that LPS increased
by 184% for p62 compared to the control microglia.
LPS-induced p62 increase in microglial cells was signifi-
cantly higher than in neurons and astrocytes where p62
fluorescence intensity increased by 80% compared to
control neurons, whereas LPS failed to significantly alter
astrocytic p62 intensity (Figure 2D).
Concerning the conversion of LC3-I to LC3-II, the
LC3-II/LC3-I ratio was calculated and represented in
Figure 2B. As expected, blockade of the autophagic flux
by Baf induced an accumulation of LC3-II; the LC3-II/
LC3-I ratio was 5.45-fold of the control. Interestingly,
the accumulation of LC3-II was more pronounced when
cells were exposed to LPS in condition of blockade of
the autophagic flux; LPS increased by 50% LC3-II/LC3-I
ratio as compared to Baf alone. C16 failed to prevent
this increase and Aβ42 had no effect.
Co-labeling of LC3, MAP2 for neurons, GFAP for astro-
cytes, and CD68 for microglia in the tri-culture (Figure 2E
for microglia and see Additional file 2 for neurons and as-
trocytes) showed that, similarly to what was observed for
Figure 2 Changes in autophagic factors after exposure to LPS or Aβ42 in primary tri-cultures. Representative immunoblots show the
immunoreactivity of (A) p62, (B) LC3-I, LC3-II, and β-actin from cell lysates of primary tri-cultures exposed to 20 μM Aβ42 or 100 ng/mL LPS pretreated
or not with 210 nM C16 in serum-free medium for 48 hours, treated or not with an autophagic flux inhibitor bafilomycin A1 (Baf) at 50 nM for 24 hours
before cell lysis. Densities were quantified using GeneTools software. Data of each protein were reported to data of the corresponding β-actin.
The results are expressed as arbitrary units (percentage of the control set at 100%) and are mean ± SEM from six independent experiments
in duplicate. Co-labeling of autophagic receptor (C) p62 (green) or (E) LC3 (green), CD68 for microglia (red), GFAP for astrocytes (blue), and
DAPI for nuclei (cyan) in tri-cultures seeded on coverslips. All images were from a compilation of the entire z-series sections acquired by
confocal microscopy (Olympus IX-81). A white square represents a magnified ROI. Scale bars, 42 μm. Fluorescence intensity of (D) p62 and
(F) LC3 staining in neurons, astrocytes, and microglia quantified using ImageJ software in confocal images. ***P <0.001 compared to control; †††P <0.001
compared to C16; ##P <0.01, ###P <0.001 compared to Baf; $$P <0.01 compared to Baf with C16; £££P <0.001 compared to LPS treatment in microglia by
one-way ANOVA with a Newman-Keuls multiple comparison test. Baf, bafilomycin A1; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary
acidic protein; LPS, lipopolysaccharide; NS, not significant; ROI, region of interest.
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p62, the largest LPS-induced increase in LC3 fluorescence
intensity was observed in microglia and was significantly
different from that quantified in neurons and astrocytes
under LPS stress (56%, 116%, and 240% in neurons, astro-
cytes, and microglia compared to their respective control)
(Figure 2F).
Using the Lyso-ID Red dye, an acidic organelle-selective
dye, confocal images showed that many acidic vesicles
were accumulated in tri-cultures treated with LPS, specif-
ically in cells with microglial-like morphology (Figure 3).
Merged images revealed that p62- and LC3-positive
puncta largely co-localized with Lyso-ID-positive dots
(Figure 3A,B, respectively).
Beclin-1 expression was not affected by LPS or Aβ42
treatments (data not shown).
Activation of mTOR signaling pathway in primary tri-cultures
mTOR activation leads to phosphorylation of various
substrates, in particular p70S6K at T389, a ribosomal S6
kinase involved in ribogenesis [26,27] and is also known
as a negative regulator of autophagy; activation of
mTOR leads to the inhibition of autophagy, whereas
its inhibition by rapamycin activates autophagy.
Figure 4A shows that mTOR activation was only in-
creased in the LPS with Baf condition (33% increase)
which was significantly prevented by the addition of
C16. Concerning p70S6K activation, LPS induced an in-
crease in PT389-p70S6K/p70S6K (43%) which was pre-
vented by C16, while Aβ42 decreased p70S6K activation
(44%) which was maintained in the presence of C16.
When the autophagic flux was blocked by Baf, p70S6K
activation was inhibited (Figure 4B).
These results showed that: 1) only severe inflammatory
stress induced by LPS led to an accumulation of acidic
vesicles containing p62 and LC3 autophagic markers.
Significant prevention of the rate of inflammatory factors
by the C16 compound did not prevent the induction of
autophagy; and 2) to our surprise, Aβ42 did not alter the
rate of autophagic factors and did not induce inflamma-
tory stress 48 hours after treatment compared to the
control. We wanted to know whether an exogenous in-
flammatory stress in the presence of Aβ42 could alter
autophagy by targeting three main cytokines, TNF-α,
IL-1β, and IL-6, well-known in AD [15,28].
Effect of exogenous inflammatory factors with Aβ42 in
tri-cultures
Autophagy
Preliminary studies have shown that a cocktail of three
cytokines (IL-1β, TNF-α, and IL-6) at doses ranging
from 100 and 1,000 pg/mL in tri-cultures induced dele-
terious morphological changes starting at the dose of
Figure 3 Immunostaining of acidic vesicles and p62 or LC3 under inflammatory stress in primary tri-cultures. Co-labeling of autophagic
receptor (A) p62 (green) or (B) LC3 (green), Lyso-ID for acidic vesicles (red), and DAPI for nuclei (cyan) in tri-cultures seeded on coverslips, exposed to
20 μM Aβ42 or LPS 100 ng/mL in serum-free medium for 48 hours. All images were from a compilation of the entire z-series sections acquired by
confocal microscopy (Olympus IX-81). A white square represents a magnified ROI. Two-dimensional fluorograms display the intensity and
distribution of different colored pixels within the magnified ROI in the merged image. Scale bars, 42 μm. DAPI, 4′,6-diamidino-2-phenylindole;
LPS, lipopolysaccharide; ROI, region of interest.
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400 pg/mL for 48 hours. Therefore, in the following ex-
periments, the dose of 200 pg/mL was chosen because
the cell integrity was preserved. In addition, the effects
of each factor at a dose of 200 pg/mL on both inflamma-
tory and autophagic components were determined in the
presence or absence of 20 μM Aβ42.
As in the LPS condition, any change in Beclin-1 ex-
pression was observed by either the cocktail or individ-
ual inflammatory factors with or without Aβ42 or Baf
(data not shown).
In the absence of Baf, IL-1β and the inflammatory
cocktail increased p62 by 94% and 253%, respectively,
compared to the control. Furthermore, these inflamma-
tory stresses applied with Aβ42 also increased the ex-
pression of p62 (60% and 98%, respectively), while Aβ42
alone had the tendency to decrease the level of expres-
sion of p62 (Figure 5A). Interestingly, C16 only pre-
vented an IL-1β-induced increase in p62 with or without
Aβ42. In the presence of Baf, the inflammatory cocktail
and IL-1β enhanced the p62 expression with or without
Aβ42 (Figure 5A) as it was observed for LPS in Figure 2A.
However, the induction of inflammatory stress with TNF-α
or IL-6 alone did not impair p62 expression [see Additional
file 3A]. Consequently, confocal microscopy staining
was only performed in cells treated with exogenous IL-1β
and showed that microglia displayed significantly higher
fluorescent p62 staining (12.4 times higher than the
control microglia) compared to neurons and astrocytes
(fluorescence intensity of 3.8 and 5.3 times higher than
their respective controls) (Figure 5B,C). Furthermore,
C16 treatment prevented the p62-positive staining in all
cell types and, interestingly, p62 fluorescent intensity was
also reduced by Aβ42 in microglia (Figure 5C). Accumula-
tion of acidic vesicles stained by Lyso-ID and co-localized
with p62 was prevented by C16 treatment in the IL-1β
stress condition (Figure 5D).
Regarding LC3, western blot analysis showed that in
the presence of Baf, inflammatory cocktail and IL-1β
with or without Aβ42 increased the LC3-II/LC3-I ratio
compared to Baf alone (Figure 6A). Contrary to LPS
(Figure 2B), the compound C16 prevented these in-
creases of the LC3-II/LC3-I ratio compared to Baf alone
(Figure 6A). Similarly to what was observed for p62,
TNF-α or IL-6 did not modify the LC3-II/LC3-I ratio
with or without Aβ42 [see Additional file 3B]. LC3 im-
munostaining showed that under IL-1β stress, microglia
displayed diffuse LC3 staining in the cytoplasm which
was not prevented by C16 (Figure 6B). IL-1β induced
more expression of LC3 in microglia than in astrocytes
(207% and 113% increase of fluorescent intensity in
microglia and astrocytes, respectively) (Figure 6C). Fur-
thermore, co-labeling of LC3 and Lyso-ID showed that
LC3 was found in many acidic vesicles under IL-1β
stress with or without Aβ42 (Figure 6D).
Figure 4 Activation of mTOR signaling pathway by inflammatory stress in primary tri-cultures. Representative immunoblots show the
immunoreactivity of (A) mTOR, PS2448-mTOR, (B) p70S6K, PT389-p70S6K, and β-actin from cell lysates of primary tri-cultures exposed to 20 μM
Aβ42 or 100 ng/mL LPS pretreated or not with 210 nM C16 in serum-free medium for 48 hours, treated or not with an autophagic flux inhibitor
bafilomycin A1 (Baf) at 50 nM 24 hours before cell lysis. Densities were quantified using GeneTools software. Data of each protein were reported
to data of the corresponding β-actin. The results are expressed as arbitrary units (percentage of the control set at 100%) and are mean ± SEM from
six independent experiments in duplicate. ***P <0.001 compared to control; †††P <0.001 compared to LPS; ###P <0.001 compared to Baf; ‡‡‡P <0.001
compared to LPS with Baf; &P <0.05 compared to C16 by one-way ANOVA with a Newman-Keuls multiple comparison test. Baf, bafilomycin A1; LPS,
lipopolysaccharide, mTOR, mammalian target of rapamycin.
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Figure 5 Changes of p62 with cytokine cocktail or IL-1β stress in primary tri-cultures. (A) Representative p62 and β-actin immunoblots
from cell lysates of primary tri-cultures exposed or not to 20 μM Aβ42 pretreated or not with 210 nM C16 in serum-free medium and treated with
a cytokine cocktail of 200 pg/mL of IL-1β, TNF-α, and IL-6 or with IL-1β alone for 48 hours, treated or not with an autophagic flux inhibitor bafilomycin
A1 (Baf) at 50 nM 24 hours before cell lysis. Densities were quantified using GeneTools software. Data of each protein were reported to data of the
corresponding β-actin. The results are expressed as arbitrary units (control set at 100%) and are mean ± SEM from six independent experiments
in duplicate. (B) Co-labeling of the autophagic receptor p62 (green), CD68 for microglia (red), GFAP for astrocytes (blue), and DAPI for nuclei (cyan) in
tri-cultures. (C) Fluorescence intensity of p62 staining in cells quantified using ImageJ software in confocal images. (D) Co-labeling of the autophagic
receptor p62 (green), Lyso-ID (red), and DAPI for nuclei (cyan) in tri-cultures. In (B) and (D), all images were from a compilation of the entire z-series
sections acquired by confocal microscopy. A white square represents a magnified ROI. Two-dimensional fluorograms display the intensity
and distribution of different colored pixels within the magnified ROI. Scale bars, 42 μm. ***P <0.001 compared to control; §§§P <0.001 compared
to Aβ42; ††P <0.01, †††P <0.001 compared to IL-1β; δP <0.05, δδδP <0.001 compared to IL-1β with Aβ42; ##P <0.01, ###P <0.001 compared to Baf;
&&P <0.01, &&&P <0.001 compared to Baf with Aβ42; ‡‡‡P <0.001 compared to Baf with cocktail; εεεP <0.001 compared to Baf with cocktail
and Aβ42; £££P <0.001 compared to IL-1β treatment in microglia by one-way ANOVA with a Newman-Keuls multiple comparison test. Baf,
bafilomycin A1; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; ROI, region of interest.
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Figure 6 Changes of LC3 with cytokine cocktail or IL-1β stress in primary tri-cultures. (A) Representative LC3 and β-actin immunoblots
from cell lysates of primary tri-cultures exposed or not to 20 μM Aβ42 pretreated or not with 210 nM C16 in serum-free medium and treated with
a cytokine cocktail of 200 pg/mL of IL-1β, TNF-α, and IL-6 or with IL-1β alone for 48 hours, treated or not with an autophagic flux inhibitor bafilomycin
A1 (Baf) at 50 nM for 24 hours before cell lysis. Densities were quantified using GeneTools software. Data of each protein were reported to data of the
corresponding β-actin. The results are expressed as arbitrary units (control set at 100%) and are mean ± SEM from six independent experiments in
duplicate. (B) Co-labeling of LC3 (green), CD68 for microglia (red), GFAP for astrocytes (blue), and DAPI for nuclei (cyan) in tri-cultures.
(C) Fluorescence intensity of LC3 staining in neurons, astrocytes, and microglia quantified using ImageJ software in confocal images. (D) Co-labeling of
LC3 (green), Lyso-ID (red), and DAPI for nuclei (cyan) in tri-cultures. In (B) and (D), all images were from a compilation of the entire z-series sections
acquired by confocal microscopy (Olympus IX-81). A white square represents a magnified ROI. Two-dimensional fluorograms display the
intensity and distribution of different colored pixels within the magnified ROI in the merged image. Scale bars, 42 μm.***P <0.001 compared
to control; δδδP <0.001, compared to IL-1β with Aβ42; ###P <0.001 compared to Baf; &&&P <0.001 compared to Baf with Aβ42; ‡‡‡P <0.001
compared to Baf with cocktail; εεεP <0.001 compared to Baf with cocktail and Aβ42; σσσP <0.001 compared to Baf with IL-1β; γγγP <0.001
compared to Baf with IL-1β and Aβ42; £££P <0.001 compared to IL-1β treatment in microglia by one-way ANOVA with a Newman-Keuls multiple
comparison test. Baf, bafilomycin A1; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; ROI, region of interest.
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Analysis of mTOR signaling showed that contrary to
LPS, the inflammatory cocktail or each cytokine tested
alone failed to activate mTOR [see Additional file 4A].
However, the inflammatory cocktail, TNF-α, and IL-6 ac-
tivated p70S6K as shown for LPS and this activation was
prevented by C16 only in the case of the inflammatory
cocktail [see Additional file 4B]. In addition, Aβ42 sig-
nificantly decreased p70S6K activation even in the pres-
ence of the inflammatory cocktail and cytokines TNF-α
and IL-6 alone (between 45% and 60%). A decrease of
PT389-p70S6K/p70S6K was also observed in the presence
of IL-1β (67% and 64% with or without C16, respect-
ively) [see Additional file 4B].
Inflammatory levels
The cytokine cocktail (200 pg/mL of IL-1β, TNF-α, and
IL-6) and IL-1β (200 pg/mL) alone in tri-cultures of
neurons/astrocytes/microglia induced a great increase of
all cytokines in the intracellular compartment after
48 hours of treatment (Figure 7). Indeed, intracellular
IL-1β levels were 3 to 8 times higher and 4 to 12 times
higher than the control with cocktail and IL-1β treat-
ment, respectively. While with cocktail, C16 had no ef-
fect, it significantly prevented the increase in the
intracellular IL-1β induced by exogenous IL-1β with or
without Aβ42 (Figure 7A). Intracellular TNF-α increases
(about 12% with cocktail and 40% with IL-1β treatment)
were observed and as for IL-1β, C16 only prevented the
TNF-α production induced by IL-1β treatment (Figure 7B).
Cocktail or IL-1β treatment induced an increase of
intracellular IL-6 levels (90 and 200 times higher than
the control, respectively). However, C16 prevented
cocktail-induced production of IL-6 without Aβ42 and
as for TNF-α and IL-1β, it inhibited the production of
IL-6 induced by IL-1β treatment with or without Aβ42
(Figure 7C).
In the extracellular compartment, IL-1β levels with
cocktail or IL-1β alone treatments were similar and
lower than the dose treatment (mean: 96.68 ± 6.82 pg/mL)
(Figure 7D). TNF-α levels induced by cocktail were similar
to dose treatment (mean: 241.60 ± 19.50 pg/mL), while
with IL-1β treatment, an increase was observed (P <0.001)
without Aβ42 and compared to cocktail, and significantly
prevented by C16 (66% and 69% in the absence or pres-
ence of Aβ42, respectively) (Figure 7E).
Extracellular IL-6 levels were higher than the amount
included in exogenous cocktail (mean: 5143 ± 510 pg/mL
versus 200 pg/mL in cocktail treatment) and a great re-
lease was also observed with IL-1β treatment (mean:
3643 ± 481 pg/mL) with no rescue by C16 (Figure 7F).
Concerning treatments of tri-cultures with TNF-α or
IL-6 alone at 200 pg/mL, IL-1β and intracellular TNF-α
and IL-6 levels were under the limit of detection. In the
extracellular compartment, TNF-α treatment did not
modify IL-6 levels, while IL-6 treatment induced a re-
lease of TNF-α (mean: 20.10 ± 2.97 pg/mL) but C16 had
no effect [see Additional file 5].
This part of the results showed that: 1) a more moder-
ate inflammation than previously induced by LPS also
led to an accumulation of acidic vesicles containing LC3
and p62 even in the presence of Aβ42 in the tri-cultures;
2) this effect is ascribed only to IL-1β; 3) interestingly,
the C16 compound prevented not only the production
of intracellular factors TNF-α and IL-1β induced by ex-
ogenous IL-1β but also the accumulation of p62 and
LC3 in acidic vesicles; and 4) again, we found that in-
creases in p62 and in the conversion of LC3-I in LC3-II
were more pronounced in microglia, where Aβ42 re-
versed the IL-1β-induced increase in p62, underlying an
increased sensitivity of microglial autophagy to inflam-
matory stress in an integrated cellular environment
modeling the brain parenchyma. We then wanted to
confirm that the global changes of autophagy observed
in tri-cultures mainly results from changes of microglial
autophagy. Given the drastic alterations on neurons in
these conditions, we investigated the impact of exogen-
ous IL-1β with or without Aβ42 on purified cultures of
astrocytes or microglia.
Inflammation and autophagy in purified microglia and
astrocyte cultures
Inflammatory level
Treatment of microglia with 200 pg/mL IL-1β for
48 hours induced a great increase of intracellular cyto-
kines. In fact, IL-1β levels were 6 to 10 times higher than
respective controls except in the presence of Aβ42 where
levels were similar to Aβ42 alone (Figure 8A). The C16
treatment partially prevented IL-1β production (35%,
P <0.05) induced by exogenous IL-1β without Aβ42.
However, C16 reversed the inhibitory Aβ42 effect on
IL-1β production (Figure 8A). For TNF-α, exogenous
IL-1β only increased intracellular levels in the pres-
ence of Aβ42 and C16 (Figure 8B). For IL-6, intracel-
lular levels increased by a factor of 20 to 66 compared
to respective controls except in Aβ42 with IL-1β treat-
ment where they were similar to Aβ42 alone (Figure 8C).
The C16 treatment did not prevent IL-6 production in-
duced by exogenous IL-1β without Aβ42. However, C16
blocked the Aβ42 inhibitory effect on IL-6 production
(Figure 8C).
In the extracellular compartment, results showed that
Aβ42 decreased IL-1β levels (35%, P <0.01). The C16
treatment also decreased IL-1β levels (21%, P <0.05)
without Aβ42. However, in the presence of Aβ42, C16
blocked the effect of Aβ42; extracellular IL-1β levels
were similar to the dose treatment (Figure 8D).
Exogenous IL-1β induced a great increase of extracellu-
lar levels of TNF-α (mean: 108.40 ± 8.10 pg/mL for IL-1β
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alone or with both Aβ42 and C16). However, Aβ42 de-
creased TNF-α levels induced by IL-1β treatment (49%,
P <0.01). The C16 also decreased TNF-α levels induced by
IL-1β treatment (35%, P <0.05). However, in the presence
of Aβ42, C16 blocked the effect of Aβ42 (Figure 8E). As
for TNF-α, exogenous IL-1β significantly increased
extracellular levels of IL-6 in all conditions (mean: 766.40 ±
114.60 pg/mL) (Figure 8F). However, Aβ42 decreased IL-6
levels induced by IL-1β treatment (44%, P <0.01). C16
blocked the inhibitory effect of Aβ42 (Figure 8F).
In astrocytes, IL-1β treatment did not induce produc-
tion of IL-1β [see Additional file 6A] and in the
Figure 7 Cytokine levels induced after an inflammatory cocktail or IL-1β stress in primary tri-cultures. Cytokine (IL1-β, TNF-α, and IL-6)
levels in cell lysates (A, B, C, respectively) and in culture medium (D, E, F, respectively) of tri-cultures pre-treated or not with 210 nM C16 and
exposed or not to 20 μM Aβ42, and treated with a cocktail of IL-1β, TNF-α, and IL-6 (200 pg/mL of each cytokine) or with 200 pg/mL IL-1β
alone in serum-free medium were analyzed by the 3-plex Luminex xMAP assay containing a mixture of specific beads for each cytokine as
described in the Methods section. Cytokine levels in cell lysates and culture medium are expressed in pg/mg protein and pg/mL, respectively.
Results are mean ± SEM for six experiments in duplicate. ***P <0.001 compared to respective control; #P <0.05, ###P <0.001 compared to inflammatory
cocktail; ††P <0.01, †††P <0.001 compared to IL-1β, εεP <0.01, εεεP <0.001 compared to IL-1β with Aβ42 by one-way ANOVA with a Newman–Keuls
multiple comparison test.
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extracellular compartment, levels were significantly de-
creased compared to the dose added in the medium
(mean: 43.17 ± 4.42 pg/mL versus 200 pg/mL). In the
presence of C16, results showed an increase in extracel-
lular IL-1β levels (36% and 50%, without and with Aβ42,
respectively) [see Additional file 6C]. IL-1β induced IL-6
production, which was higher in the presence of C16,
but IL-6 levels remained low at less than 10 pg/mL [see
Additional file 6B]. In the extracellular compartment, re-
sults were similar to those of IL-1β, with a significant in-
crease in the presence of C16 (100% and 176%, without
and with Aβ42, respectively) [see Additional file 6D]. For
TNF-α, levels were under the limit of detection.
Autophagy monitoring in microglia and astrocytes
Concerning p62 in microglial cell cultures, treatment
with IL-1β alone or combined with Aβ42 increased p62
by 30%, whereas Aβ42 alone had no effect. P62 in-
creased by 92% and 173% with Baf alone and IL-1β plus
Baf, respectively (Figure 9A). Aβ42 partially reversed the
Baf-induced increase of p62 (40%, P <0.001) and signifi-
cantly prevented the p62 increase induced by IL-1β
combined with Baf (37%, P <0.001) (Figure 9A).
Regarding the LC3-II/LC3-I ratio, Aβ42 and IL-1β
alone or combined had no significant effect without Baf.
However, in the presence of Baf, the LC3-II/LC3-I ratio
increased by 329% and 300% for Baf alone and Baf with
Figure 8 Cytokine levels induced by inflammatory stress in microglia. Cytokine (IL1-β, TNF-α, and IL-6) levels in cell lysates (A, B, C, respectively)
and in culture medium (D, E, F, respectively) of primary microglia pre-treated or not with 210 nM C16, exposed or not to 20 μM Aβ42, and
treated with 200 pg/mL of IL-1β in serum-free medium were analyzed by the 3-plex Luminex xMAP assay containing a mixture of specific beads
for each cytokine as described in the Methods section. Cytokine levels in cell lysates and culture medium are expressed in pg/mg protein and
pg/mL, respectively. Results are mean ± SEM for six experiments in duplicate. *P <0.05, **P <0.01, ***P <0.001 compared to respective control;
†P <0.05, ††P <0.01, †††P <0.01 compared to IL-1β; εP <0.05, εεP <0.01, εεεP <0.001 compared to Aβ42 with IL-1β by one-way ANOVA with a
Newman–Keuls multiple comparison test.
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Figure 9 Changes in autophagic factors in microglia. Representative immunoblots show the immunoreactivity of (A) p62, (B) LC3-I, LC3-II,
and β-actin from cell lysates of primary microglia pretreated or not with 210 nM C16 and exposed or not to 20 μM Aβ42 in serum-free medium
containing or not 200 pg/mL of IL-1β for 48 hours. The autophagic flux inhibitor bafilomycin A1 (Baf) at 50 nM was added or not for 24 hours
before cell lysis. Densities were quantified using GeneTools software. Data of each protein were reported to data of the corresponding β-actin.
The results are expressed as arbitrary units (percentage of the control set at 100%) and are mean ± SEM from six independent experiments in
duplicate. ***P <0.001 compared to control; §§P <0.01, §§§P <0.001 compared to Aβ42; $P <0.05, $$P <0.01 compared to Baf; ††P <0.01, †††P <0.001 com-
pared to Aβ42 with IL-1β and Baf by one-way ANOVA with a Newman-Keuls multiple comparison test. Co-labeling of the autophagic receptor (C) p62
(green) or (D) LC3 (green), Lyso-ID (red), and DAPI for nuclei (cyan) in microglia. All images were from a compilation of the entire z-series sections ac-
quired by confocal microscopy (Olympus IX-81). For (A) and (B), only merged images were selected. A white square represents a magnified ROI. Two-
dimensional fluorograms display the intensity and distribution of different colored pixels within the magnified ROI in the merged image. Scale bars, 42 μm. Baf,
bafilomycin A1; DAPI, 4′,6-diamidino-2-phenylindole; ROI, region of interest.
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Aβ42, respectively (Figure 9B). Microglial cell treatment
with IL-1β in the presence of Baf significantly reduced
the LC3-II/LC3-I ratio by 22% and 28% compared to Baf
alone or Baf plus Aβ42, respectively (Figure 9C).
Similarly to what was observed in tri-cultures, immuno-
fluorescence analysis showed that p62 increased in micro-
glia exposed to IL-1β with or without Aβ42. P62 was
largely found within acidic vesicles stained with Lyso-ID
[see Additional file 7A]. In the presence of Baf autophagy
inhibitor, the accumulation of p62 co-localized with Lyso-
ID was even more pronounced and, interestingly, was pre-
vented by Aβ42 with or without IL-1β (Figure 9C). While
no difference was observed in LC3 expression without Baf
(Figure 9B and see Additional file 7B), co-immunostaining
of LC3 and Lyso-ID was positive in the presence of Baf
with or without Aβ42 which was prevented by the IL-1β
treatment (Figure 9D).
The inhibitory effect of Aβ42 on the production of in-
flammatory factors and accumulation of acid vesicles
containing p62 induced by IL-1β was not an effect on
cell death because the result of the MTS test (Promega,
Charbonnières les Bains, France) showed no difference
compared to the control microglia (100.00 ± 4.00% and
103.60 ± 2.86% cell viability for control microglia and
Aβ42-treated microglia, respectively; n = 6 experiments
in duplicate).
In microglia, Aβ42 treatment induced a decrease of
Beclin-1 of 42% and 54% without or with C16 pre-
treatment, respectively, which was suppressed by IL-1β
treatment (Figure 10A). As in tri-cultures, Aβ42 decreased
the expression of Beclin-1 in the Baf condition which was
also inhibited by IL-1β treatment (Figure 10A).
Contrary to tri-cultures, Aβ42 and IL-1β alone or
combined significantly decreased the mTOR activation
which was not prevented by C16 pre-treatment in
microglia (between 30% and 50%) (Figure 10B). Further-
more, these inhibitions were associated with a great de-
crease of PT389-p70S6K/p70S6K ratio (between 40% and
60%) as shown in Figure 10C. As in tri-cultures, Baf de-
creased both mTOR and its downstream substrate
p70S6K activations (Figure 10B,C).
In astrocytes no changes in autophagic factors were
observed except in the presence of Baf where all of them
were increased [see Additional file 8A,B,C]. Aβ42 and
IL-1β alone or in association significantly inhibited the
mTOR signaling pathway not prevented by C16 [see
Additional file 8D,E].
The latest results obtained in purified microglia showed
that: 1) exogenous IL-1β induced p62 accumulation in
acidic vesicles and production of IL-1β and TNF-α which
were significantly prevented by Aβ42, suggesting that
amyloid peptide could maintain microglia defense; 2) the
C16 compound inhibited the effects of Aβ42, indicating
that its inhibitory role on PKR activation could be
dangerous for microglial autophagy (see Discussion sec-
tion); and 3) contrary to microglia, exogenous IL-1β did
not induce autophagy in purified astrocytes.
Discussion
Different studies have demonstrated a close relationship
between inflammation and autophagy in Crohn’s disease
[29], cancer [30], cutaneous inflammation [31], and dia-
betes [32]. Inflammation also constitutes a key compo-
nent in the pathogenesis of AD. Therefore, multiple
anti-inflammatory treatments have been tested but they
were not satisfactory [33]. Furthermore, autophagy has
been shown to be impaired in AD with accumulation of
AVs containing proteins for Aβ production [8,9]. For the
first time, this study brought out the links between
autophagy and inflammation in AD using a primary
tri-culture modeling the brain parenchyma by includ-
ing neurons, astrocytes, and microglia as previously
described [17].
We first treated tri-cultures with LPS, known to in-
duce autophagy and to produce cytokines through Toll-
like receptor (TLR)-4 activation [34,35]. Interestingly,
under this robust inflammatory input, microglia was
very reactive with many p62- and LC3-positive puncta in
cytoplasm and ramified processes, suggesting autophagy
induction specifically in microglia, while neurons were
condensed with very short extensions or died and many
astrocytes were stellar without p62 and LC3 signals.
Moreover, this immunostaining was predominantly
co-localized with the Lyso-ID Red dye staining acidic
vesicles. TLR is well known as a major innate immune
sensor and has been shown to mediate autophagy
through the recruitment of different protein adaptors
such as p62 [36]. However, the LC3-II/LC3-I ratio
was not changed compared to the control, except in
the presence of bafilomycin, an inhibitor of autoph-
agy, indicating that LPS induces autophagy in our ex-
perimental settings, confirming previous findings.
Unexpectedly, treatment of tri-cultures with Aβ42 did
not affect the expression of p62 and the LC3-II/LC3-I
ratio, except in the presence of Baf where p62 expression
significantly decreased. Aβ42 alone did not modify au-
tophagy in the serum-free conditions where a basal in-
flammation was similar to the control after 48 hours of
treatment. Other studies showed that Aβ neurotoxicity
induced cytokine mRNA expression [37,38] but few data
are available concerning TNFα, IL-1β, and IL-6 by
ELISA after Aβ42 treatment in vitro. Meda et al. [39] in-
dicated that production of TNFα in Aβ25-35-treated
microglia was only observed after stimulation by IFN-γ.
Other studies showed in microglia that oligomers were
only inducers of inflammatory factors but not the fibril-
lar form of amyloid peptide [40]. Furthermore, in human
fetal microglia, it was shown that Aβ42 induced release
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of TNFα and IL-1β but levels were around 10 and
8 pg/mL, respectively, accordingly to our results [41].
These last authors also showed that the production
was enhanced by IL-8.
To gain a better understanding of the autophagic
process, we checked the mTOR signaling pathway. In
our conditions, the mTOR activation was similar with
LPS or Aβ42, except with Baf where LPS increased the
mTOR activation. The p70S6K activation was increased
by LPS and conversely decreased with Aβ42 as previ-
ously described [42,43].
Taken together, LPS, a robust inflammatory inducer,
activated the mTOR/p70S6K pathway and induced au-
tophagy with accumulation of many acidic p62- and
LC3-positive vesicles in our experimental conditions.
Many studies support this LPS toxicity [44-48]. However,
Aβ42, which induced a low grade of inflammation,
inhibited the activation of the mTOR pathway and could
Figure 10 Activation of mTOR signaling pathway in microglia. Representative immunoblots show the immunoreactivity of (A) Beclin-1,
(B) mTOR, (C) PS2448-mTOR, p70S6K, PT389-p70S6K, and β-actin from cell lysates of primary microglia pretreated or not with 210 nM C16 and
exposed or not to 20 μM Aβ42 in serum-free medium and treated with 200 pg/mL of IL-1β for 48 hours, treated or not with an autophagic
flux inhibitor bafilomycin A1 (Baf) at 50 nM for 24 hours before cell lysis. Densities were quantified using GeneTools software. Data of each
protein were reported to data of the corresponding β-actin. The results are expressed as arbitrary units (percentage of the control set at
100%) and are mean ± SEM from six independent experiments in duplicate. ***P <0.001 compared to control; §§§P <0.001 compared to Aβ42;
&&&P <0.001 compared to C16 by one-way ANOVA with a Newman-Keuls multiple comparison test. Baf, bafilomycin A1; mTOR, mammalian
target of rapamycin.
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activate autophagy. For the first time, we described the
role of Aβ42 on the autophagic flux in primary neurons,
astrocytes, and microglia. Only one in vitro study has ex-
amined the autophagy using SH-SY5Y cells exposed to
Aβ42 and showed autophagosome accumulation [49].
Besides, many authors have shown AVs in transgenic
mouse models but the inflammation is severe in mice
and often studied at a very advanced age [49-52]. Thus,
Aβ42 alone could stimulate autophagy at early stages of
the disease and progressively a deleterious flux of au-
tophagy could take place with inflammatory input.
The C16 compound known for its anti-inflammatory
properties via the PKR inhibition [17,20,53] prevents at
least 50% of the production and release factors IL-1β,
TNF-α, and IL-6 (except its release) induced by LPS.
However, this effect while reducing the LPS-induced ac-
tivation of mTOR/p70S6K did not rescue the induction
of autophagy. It is clear that mTOR is involved in innate
and adaptive immunity [54,55]. Indeed, the mTOR acti-
vation induced cytokine production, which in turn can
also activate mTOR [56,57]. C16 by inhibiting cytokine
production can inhibit the mTOR pathway. Thus, the
robust inflammation by LPS could alter autophagy inde-
pendently of mTOR. Furthermore, C16 did not prevent
IL-6 release induced by LPS, and recently it was shown
that this cytokine can promote the maturation of autop-
hagosomes by regulating extracellular signal-regulated
kinase (ERK) which is not a target of C16 [58] and IL-6
can inhibit autophagy through interaction of STAT3
with PKR [59].
In a second part, as Aβ42 did not modify autophagy in
tri-cultures contrary to LPS and in order to better
understand cytokine involvement in autophagy regula-
tion in AD, we tested the impact of a cytokine cocktail
(IL-1β, TNF-α, and IL-6) and each cytokine alone in tri-
cultures exposed to Aβ42. Some studies demonstrated
that cytokines such as TNF-α, IL-1β, and IL-6 can in-
duce autophagy in infected macrophages as a defense
mechanism [60]. However, only a cytokine cocktail or
IL-1β increased the p62 expression and LC3-II/LC3-I
ratio (with Baf ) as LPS with or without Aβ42. By co-
immunostaining, tri-cultures treated with cocktail or
IL-1β displayed p62- and LC3-positive puncta co-
localized with acidic vesicles in reactive microglia as in
LPS. Contrary to the cocktail, the autophagic changes
observed with exogenous IL-1β were rescued by C16
which partially inhibited all cytokine production in-
duced by the exogenous IL-1β treatment. By inhibiting
the PKR pathway, C16 could prevent inflammasome
formation. Indeed, PKR physically interacts with inflam-
masome components, leading to inflammasome activation
which produces IL-1β from pro-IL-1β by caspase-1 cleav-
age [21]. Furthermore, autophagy is a novel evolutionarily
conserved function of the PKR pathway that is targeted by
viral virulence gene products [61,62] and in cancer where
anti-tumor effects induce autophagosome formation
through PKR activation [63].
Contrary to LPS and the cytokine cocktail, IL-1β
inhibited the p70S6K activation as Aβ42 that would sup-
port a compensatory stimulation of autophagy. However,
IL-1β also showed an accumulation of acidic vesicles
loaded with p62 and LC3 unlike Aβ42 alone.
These findings suggest that IL-1β could be a critical
inducer of autophagy dependent on the PKR activation
and associated to a great accumulation of acidic vesicles
with or without Aβ42, suggesting a regulation of autoph-
agy by IL-1β with the progression of the disease. How-
ever, IL-1β has a controversial role in AD depending on
experimental models. Indeed, some authors demonstrated
that IL-1β overexpression decreased amyloid deposits in
inducible APP/PS1-IL-1βXAT or 3xTgAD-IL-1βXAT mice
receiving a unilateral stereotactic injection of FIV-Cre, but
exacerbated tau pathology [64,65]. They also observed in-
filtrating inflammatory neutrophils, suggesting an involve-
ment of peripheral cells to eliminate amyloid deposits as
previously described [66]. On the contrary, blocking IL-1β
decreased pro-inflammatory cytokines, enhanced micro-
glial phagocytosis of Aβ, and rescued cognition and tau
pathology in 3xTgAD treated with intraperitoneal anti-
IL-1 receptor [67]. Recently, APP/PS1 mice with NLRP3
inflammasome deficiency were largely protected from the
loss of spatial memory and resulted in decreased Aβ de-
posits [16]. In many AD transgenic mice, autophagic flux
was inhibited with accumulation of AVs, but it is well
established that autophagy regulates IL-1β secretion [6] by
degradation of inflammasome [68,69]. Thus, a therapeutic
strategy aiming to enhance autophagy in AD could be at-
tractive to limit the deleterious effects of IL-1β.
Interestingly, accumulation of acidic p62+ and LC3+
vesicles by LPS, cytokine cocktail, or IL-1β was observed
in cells that looked like microglia. In a third part, to con-
firm, we investigated the IL-1β treatment in purified
microglia and astrocytes. For these last cells, any change
was observed in the p62 expression and LC3-II/LC3-I
ratio, while the mTOR/p70S6K activation decreased with
or without Aβ42. While the role of astrocytes is increas-
ingly appreciated [70], their autophagic process has
never been studied in AD. In severe lysosomal storage
disorders, Di Malta et al. [71] showed that autophagy in
astrocytes was impaired.
In purified microglia cultures, the IL1-β treatment in-
duced the production of cytokines prevented by Aβ42 in
the absence of C16. As the mTOR pathway was inhibited
with both Aβ42 and IL1-β, the decrease of IL1-β-induced
cytokine production by Aβ42 could not be explained by
alteration of protein synthesis. In addition, no microglia
death was observed with Aβ42. This cytokine inhibition
by Aβ42 was lost in the presence of the PKR inhibitor,
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indicating the involvement of this kinase in the cytokine
production in microglia. Aβ42 by activating PKR could in-
duce a defense reaction of microglia as non-viral patho-
gens which induced autophagy by PKR activation [72].
Thus, in microglia, it could be proposed that a PKR-
dependent autophagy could be playing a positive role to
limit IL-1β toxicity. In microglia, Aβ42 decreased Beclin-1
and p62 without modification of the LC3-II/LC3-I ratio.
Interestingly, Lyso-ID Red vesicles were less loaded
with autophagic markers than with IL1-β, suggesting
no impairment of autophagic flux in our experimental
conditions. These findings were in accordance with
data that showed that active autophagy reduced IL1-β
production [5] and inflammasome deficiency in AD
mouse models limited Aβ deposits and improved micro-
glial phagocytosis [16].
It should be noted that these results in purified
microglia are not completely congruent with those in
tri-cultures. The microglia was more amoeboid with
less p62 expression and decreased LC3-II/LC3-I ratio
than in the tri-cultures where changes in autophagic
factors were more sustained in microglia and extended
many ramified processes. An increasing body of evi-
dence suggests that neurons, astrocytes, and microglia
cooperation influence inflammatory environment and
their own activation [73-75].
Conclusion
These results highlight that IL-1β induced autophagy
with accumulation of many acidic vesicles loaded with
p62 and LC3 in microglia of tri-cultures and purified
microglia. Interestingly, Aβ42 maintains autophagy in
microglia and prevents effects of exogenous IL-1β in the
production of inflammatory factors and in the autophagy
impairment. In microglia, Aβ42 could generate an opti-
mal host immune response through an active PKR-
dependent autophagy.
Therefore, a better understanding of IL-1β levels and
autophagy status in AD brains according to the stage of
the disease would allow improved targeting of anti-IL-1β
and pro-autophagic therapies to reduce cognitive decline.
Additional files
Additional file 1: Cytokine levels induced by inflammatory stress in
autophagy inhibitory condition. Cytokine (IL1-β, TNF-α and IL-6) levels in
culture medium (A, B, C, respectively) and in cell lysates (D, E, F, respectively)
of tri-cultures in serum-free medium treated with an autophagic flux inhibitor,
50 nM bafilomycin A1 (Baf), with 100 ng/mL LPS or with 20 μM Aβ42 and
pre-treated or not with 210 nM C16, were analyzed by the 3-plex Luminex
xMAP assay containing a mixture of specific beads for each cytokine as de-
scribed in the Methods section. Cytokine levels in culture medium and cell
lysates are expressed in pg/mL and pg/mg protein, respectively. Results
are mean ± SEM for six experiments in duplicate. ***P <0.001 compared
to Baf alone; ###P <0.001 compared to LPS with Baf; †P <0.05, ††P <0.01,
†††P <0.001 compared to Baf with C16 by one-way ANOVA with a
Newman-Keuls multiple comparison test. Baf, bafilomycin A1; LPS,
lipopolysaccharide.
Additional file 2: Immunofluorescence of p62 and LC3 in neurons
and astrocytes under inflammatory stress in primary tri-cultures.
Co-labeling of autophagic factor (A) p62 (red) or (B) LC3 (red), MAP2 for
neurons (green), GFAP for astrocytes (blue), and DAPI for nuclei (cyan) in
tri-cultures seeded on coverslips and exposed to 20 μM Aβ42 or LPS
100 ng/mL in serum-free medium for 48 hours. All images were from a
compilation of the entire z-series sections acquired by confocal microscopy
(Olympus IX-81). A white square represents a magnified ROI. Scale bars,
42 μm. DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic
protein; LPS, lipopolysaccharide; MAP2, microtubule-associated protein 2;
ROI, region of interest.
Additional file 3: Changes in autophagic factors under
inflammatory stress. Representative immunoblots show the
immunoreactivity of (A) p62, (B) LC3-I, LC3-II, and β-actin from cell lysates
of primary tri-cultures exposed or not to 20 μM Aβ42 pretreated or not
with 210 nM C16 in serum-free medium and treated with 200 pg/mL of
TNF-α or IL-6 alone for 48 hours, treated or not with an autophagic flux
inhibitor bafilomycin A1 (Baf) at 50 nM for 24 hours before cell lysis.
Densities were quantified using GeneTools software. Data of each protein
were reported to data of the corresponding β-actin. The results are
expressed as arbitrary units (percentage of the control set at 100%) and
are mean ± SEM from six independent experiments in duplicate. ***P <0.001
compared to control; ###P <0.001 compared to Baf by one-way ANOVA with
a Newman-Keuls multiple comparison test. Baf, bafilomycin A1.
Additional file 4: Activation of mTOR signaling pathway by
exogenous cytokines in tri-cultures. Representative immunoblots
show the immunoreactivity of (A) mTOR, PS2448-mTOR, (B) p70S6K,
PT389-p70S6K, and β-actin from cell lysates of primary tri-cultures exposed
to 20 μM Aβ42, pretreated or not with 210 nM C16 in serum-free medium
and treated with a cytokine cocktail of 200 pg/mL of IL-1β, TNF-α, and IL-6
or with 200 pg/mL of IL-1β, TNF-α, or IL-6 alone for 48 hours. Densities were
quantified using GeneTools software. Data of each protein were reported to
data of the corresponding β-actin. The results are expressed as arbitrary
units (percentage of the control set at 100%) and are mean ± SEM from six
independent experiments in duplicate. ***P <0.001 compared to control;
&&P <0.01, &&&P <0.001 compared to C16; ‡‡P <0.01, ‡‡‡P <0.001 compared
to inflammatory cocktail; $P <0.05 compared to TNF-α; §§§P <0.001
compared to TNF-α with C16; †P <0.05 compared to IL-6; δP <0.05
compared to IL-6 with C16 by one-way ANOVA with a Newman-Keuls
multiple comparison test. mTOR, mammalian target of rapamycin.
Additional file 5: Cytokine levels induced by exogenous TNF-α and
IL-6. Cytokine (TNF-α and IL-6) levels in culture medium (A and B,
respectively) of tri-cultures pre-treated or not with 210 nM C16, ex-
posed or not to 20 μM Aβ42, and treated with 200 pg/mL of TNF-α
or IL-6 alone in serum-free medium were analyzed by the 3-plex
Luminex xMAP assay containing a mixture of specific beads for each
cytokine as described in the Methods section. Cytokine levels are
expressed in pg/mL. Results are mean ± SEM for six experiments in
duplicate. **P <0.01, ***P <0.001 compared to respective control by
one-way ANOVA with a Newman-Keuls multiple comparison test.
Additional file 6: Cytokine levels induced by inflammatory stress in
astrocytes. Cytokine (IL-1β and IL-6) levels in cell lysates (A and B,
respectively) and in culture medium (C and D, respectively) of primary
astrocytes pre-treated or not with 210 nM C16, exposed or not to 20 μM
Aβ42, and treated with 200 pg/mL of IL-1β alone in serum-free medium
were analyzed by the 3-plex Luminex xMAP assay containing a mixture
of specific beads for each cytokine as described in the Methods section.
Cytokine levels in cell lysates and culture medium are expressed in pg/mg
protein and pg/mL, respectively. Results are mean ± SEM for six experiments
in duplicate. ***P <0.001 compared to respective control; ††P <0.01,
†††P <0.001, compared to IL-1β; εεP <0.01, εεεP <0.001 compared to
Aβ42 with IL-1β by one-way ANOVA with a Newman-Keuls multiple
comparison test.
Additional file 7: Immunostaining of p62 or LC3 and Lyso-ID in
purified microglia. Co-labeling of the autophagic receptor (A) p62
(green) or (B) LC3 (green), Lyso-ID (red), and DAPI for nuclei (cyan) in
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microglia seeded on coverslips and exposed to 20 μM Aβ42 or 200 pg/mL
IL-1β in serum-free medium for 48 hours. All images were from a
compilation of the entire z-series sections acquired by confocal microscopy
(Olympus IX-81). A white square represents a magnified ROI. Scale bars,
42 μm. DAPI, 4′,6-diamidino-2-phenylindole; ROI, region of interest.
Additional file 8: Changes in autophagic factors in astrocytes.
Representative immunoblots show the immunoreactivity of (A) Beclin-1,
(B) p62, (C) LC3-I, LC3-II, (D) mTOR, PS2448-mTOR, (E) p70S6K, PT389-p70S6K,
and β-actin from cell lysates of primary astrocytes pretreated or not with
210 nM C16 and exposed or not to 20 μM Aβ42 in serum-free medium and
treated with 200 pg/mL of IL-1β alone for 48 hours, treated or not with an
autophagic flux inhibitor bafilomycin A1 (Baf) at 50 nM for 24 hours before
cell lysis. Densities were quantified using GeneTools software. Data of each
protein were reported to data of the corresponding β-actin. The results are
expressed as arbitrary units (percentage of control set at 100%) and are
mean ± SEM from six independent experiments in duplicate. *P <0.05,
**P < 0.01, ***P <0.001 compared to control; §§P <0.01, §§§P < 0.001
compared to Aβ42; &P <0.05, &&&P <0.001 compared to C16; ##P <0.01, ###P
<0.001 compared to IL-1β; $$$P <0.001 compared to IL-1β with Aβ42 by
one-way ANOVA with a Newman-Keuls multiple comparison test. Baf,
bafilomycin A1.
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